Introduction {#S1}
============

Alzheimer's disease (AD) is the most common form of dementia, accounting for 50--75% of all cases, and presents as a series of cognitive or behavioral symptoms including decline in memory ([@B108]; [@B77]; [@B7]). The progression of AD may drive or be exacerbated by various systemic abnormalities, such as abnormalities in systemic immunity, metabolic disorders, cardiovascular disease, and sleep disorders ([@B149]). Approximately 50 million people worldwide currently suffer from dementia, and this number is expected to triple in the next three decades due to the increasing number of aging people ([@B77]). The neuropathological hallmarks of AD are the intracellular aggregation of neurofibrillary tangles (NFTs) containing paired helical filaments (PHFs) consisting of hyperphosphorylated tau protein and the extracellular deposition of senile plaques (SPs) composed of beta-amyloid (Aβ) peptides derived from amyloid precursor protein (APP) ([@B56]; [@B12]; [@B48]; [@B129]; [@B10]; [@B64]). However, the molecular link and mechanisms underlying the pathogenesis of AD are not fully understood. Therefore, understanding the early disease mechanisms responsible for neurodegeneration in AD is critical for identifying proper diagnostic approaches and new effective therapeutic targets.

Protein phosphorylation is one of the major post-translational modifications and is involved in diverse cellular processes regulating numerous physiological and pathological processes ([@B25]; [@B112]; [@B116]; [@B16]). In particular, serine or threonine residues preceding proline (S/T-P) are the most frequently phosphorylated motifs in AD ([@B98], [@B97]; [@B93]; [@B99]; [@B62]). Interestingly, due to its unique five-carbonyl ring structure, proline is able to present as two strikingly distinct conformations, *cis* and *trans* ([@B95]; [@B128]; [@B157]; [@B153]; [@B94]; [@B99]). The peptide bond dihedral angle ω of proline residue adopts either about 0° (*cis* conformation) or about 180° (*trans* conformation), which plays critical roles in the rate-determining steps of protein folding, thus controlling the biological activity of proteins and their cellular progression ([@B150]; [@B9]; [@B40]; [@B27]). The spontaneous interconversion of *cis*/*trans* isomerization occurs slowly but can be catalyzed by a number of peptidyl-prolyl *cis*/*trans* isomerases (PPIases), such as cyclophilins, FK506-binding proteins (FKBPs), and parvulin-type PPIases ([@B40]; [@B99]). Cyclophilins and FKBPs not only belong to immunophilins which are cellular targets for the immunosuppressive drugs, but also have relationships with tau-related and Aβ pathology ([@B13]). Cyclophilin D is one of the most unique and well-studied cyclophilins, and cyclophilin D deficiency can protect neurons from Aβ- and oxidative stress-induced toxicity ([@B33], [@B34]; [@B51]). FKBP with a molecular mass of ∼52 kDa (FKBP52) is one of the most well-studied FKBPs, and FKBP52 has been shown to be highly expressed in neurons and abnormally low in AD brains ([@B47], [@B45], [@B46]). Nevertheless, the phosphorylation of an S/T-P motif further slows the spontaneous isomerization rate and renders the peptide bond against the catalytic action of known PPIases ([@B153]; [@B99]). Thus, the important discovery of Pin1 has shed light on the significance of this intrinsic conformational switch in human physiology and pathology.

Pin1 (protein interacting with NIMA (never in mitosis A)-1) was originally identified in a yeast genetic and biochemical screen for proteins involved in mitotic regulation ([@B95], [@B98]). The yeast Pin1 homolog Ess1 has been found to be the only enzyme being essential for survival among 13 PPIases since its discovery ([@B55]; [@B93]). The human Pin1 has 163 amino acids with a molecular mass of 18 kDa, containing an N-terminal WW domain (residues 1--39) characterized by two invariant tryptophans and a C-terminal PPIase domain (residues 50--163) which shares little similarity with cyclophilins and FKBPs ([@B95]; [@B128]). Pin1 is a unique and conserved PPIase that binds to specific phosphorylated proline-directed serine or threonine (pS/T-P) motifs and catalyzes the *cis/trans* isomerization of peptidyl-prolyl peptide bonds ([@B95], [@B101]; [@B128]; [@B157]; [@B132]; [@B135]). The unique substrate specificity of Pin1 results from the organization of active site residues ([@B128]; [@B98]). Specifically, the residues L122, M130, and F134 form a hydrophobic binding pocket for the substrate proline, and the cluster sequestering K63, R68, and R69 forms a positive charged phosphate binding loop which either interacts with a bound sulfate ion or facilitates binding to the pS/T-P motif ([@B128]; [@B11]; [@B84]). Further studies revealed that mutation of R68 and R69 could abolish the striking phosphorylation-specificity completely but barely affect the basic enzymatic activity ([@B157]; [@B163]; [@B98]). In addition, the WW domain has been shown to target Pin1 to the substrates since it has a higher affinity to phosphorylated peptides as compared to the PPIase domain ([@B101]; [@B140]). This Pin1-mediated conformational change of its substrates regulates numerous cellular processes, such as cell-cycle progression, cellular stress responses, development, neuronal function, immune responses, and cell death ([@B165]; [@B99]). Notably, Pin1 deregulation is implicated in age-dependent human diseases, including cancer and AD ([@B99]; [@B82]; [@B164]). Pin1 activity and expression are significantly inhibited in human AD brains and highly increased in diverse types of cancers, indicating that Pin1 might have important roles in both proliferation and degeneration ([@B100]; [@B87]; [@B17]; [@B99]; [@B82]; [@B30]; [@B164]; [@B22]).

This review focuses on the deregulation of Pin1 in AD brains, the currently understood mechanisms of tau hyperphosphorylation and APP processing associated with Pin1, and the major impact of Pin1 deregulation on AD development. This advanced understanding of the involvement of the Pin1 signaling pathway in phosphorylation will support Pin1 as a novel potential diagnostic and therapeutic target.

Regulation of Pin1 in AD {#S2}
========================

Pin1 Expression in AD {#S2.SS1}
---------------------

The significantly different levels of soluble and functional Pin1 between the brain samples of patients with AD and the control brain samples from age-matched normal subjects suggest a possible protective role of Pin1 against AD. A large amount of soluble Pin1 is dramatically depleted and sequestrated in NFTs in the human AD brain but not in age-matched normal brains ([@B100]). Pin1 expression has been further examined in the human hippocampus, a brain region that is particularly vulnerable to AD damage at early stages ([@B87]; [@B109]). In the hippocampus of normally aged brain samples, the expression of Pin1 in the CA1 region and subiculum is relatively lower than that in the CA4, CA3, and CA2 regions and presubiculum ([@B87]; [@B97]). Notably, in AD brains, NFTs predominantly occur in the CA1 region and subiculum, consistent with the finding that these subregions are prone to pyramidal neuron loss in AD ([@B29]; [@B87]). Indeed, among a randomly selected pool of 1,000 pyramidal neurons in AD, 96% of pyramidal neurons with higher expression of Pin1 seem to avoid tau-related pathology, while 71% of neurons with lower expression of Pin1 are vulnerable to NFT formation ([@B87]). On the contrary, some groups also reported that Pin1 was localized to granular vesicles but not to tau aggregates in AD ([@B57]; [@B125]; [@B28]; [@B8]). Recently, according to the hippocampal gene expression profiles of patients from three distinct age groups, the expression of Pin1 is decreased slightly in the aging group but is dramatically decreased in the AD group compared with the young group ([@B78]). These results suggest that reduced expression of Pin1 may contribute to the development of AD, including neurofibrillary degeneration.

Pin1 Genetics in AD {#S2.SS2}
-------------------

The apolipoprotein E (APOE) ε4 allele was the first definitive gene to be implicated in late-onset AD (LOAD) and is located on chromosome 19q13.2 ([@B26]; [@B60]; [@B158]). Although the human Pin1 gene is located on the same chromosome, this locus has been identified as a novel LOAD locus and is independent of APOE ([@B151]). Currently, three single nucleotide polymorphisms (SNPs) in the promoter region of the Pin1 gene have been identified to investigate their correlations with AD, including rs2287839 (-5185 G/C), rs2233678 (-842 G/C), and rs2233679 (-667 T/C). All of Pin1 polymorphism studies were conducted using genomic DNA from blood cells between AD patients and age-matched normal subjects. The polymorphism rs2233678 results in decreased Pin1 levels and is associated with a significantly raised risk of developing AD ([@B133]). The polymorphism rs2287839 leads to increased Pin1 expression and is correlated with 3-year delayed onset of LOAD ([@B105]). However, other groups showed that polymorphisms in the promoter of Pin1, rs2233678 and rs2233679, were not associated with increased LOAD risk ([@B73]; [@B113]; [@B19]). Interestingly, rs2233678 and rs2233679 have also been shown to decrease Pin1 expression and are implicated in the decreased risk of breast cancer, lung cancer, and nasopharyngeal carcinoma ([@B54]; [@B92], [@B102]). Therefore, since the controversial results remain to be elucidated, further validation of large prospective studies is needed to verify the roles of Pin1 polymorphisms in AD. Recently, a highly pathogenic and novel somatic single nucleotide variation (SNV) in Pin1 has been found in the hippocampal formation (HIF) of an AD patient ([@B117]). Since the T152M mutation is located in the C-terminal PPIase domain of Pin1, the mutation might attenuate the enzymatic activity of Pin1 and increase tau hyperphosphorylation ([@B117]). However, the molecular mechanism by which the somatic mutation regulates Pin1 activity and whether T152M knockin mice show tau-related and Aβ pathology remain to be elucidated.

Pin1 Post-translational Modification in AD {#S2.SS3}
------------------------------------------

Pin1 activity is regulated by post-translational modifications, including oxidation and phosphorylation, in AD. Neurons in the human brain are vulnerable to oxidative stress, and increased oxidative damage has been shown to be an early event in AD ([@B106]; [@B115]; [@B52]). Notably, Pin1 is modified by oxidation, leading to the loss of its activity in the hippocampus in AD ([@B17]; [@B144]). Besides, oxidized Pin1 may be recognized by the ubiquitinylation system, giving rise to the polyubiquitination ([@B147]). By employing antibodies specifically recognizing oxidized C113 of Pin1, Pin1 oxidation on C113 has been identified to inactivate the catalytic activity of Pin1, and C113-oxidized Pin1 is elevated in human AD brains compared with age-matched controls ([@B21]). It is possible that an increased percentage of C113-oxidized Pin1 in response to oxidative stress may result in the inhibition of enzymatic activity and reduction of Pin1 levels. The loss of Pin1 activity induced by oxidative stress may also result in the loss of synaptic plasticity, which is the structural basis for memory impairment in AD ([@B156]). These results suggest that the protective roles of Pin1 may be attenuated by a variety of reactive oxygen species, which are common in human AD brains.

Recently, death-associated protein kinase 1 (DAPK1) has been found to play essential roles in neuronal cell death and various neurodegenerative diseases, including AD ([@B23]; [@B68]). Importantly, DAPK1 is capable of phosphorylating Pin1 at S71 in the PPIase domain, thus inhibiting its nuclear localization, prolyl isomerase activity, and cellular function ([@B81], [@B82]). DAPK1 dramatically increases tau protein stability and hyperphosphorylation at multiple AD-related sites, which is mediated by the inhibition of Pin1 activity by phosphorylation ([@B66]). DAPK1 phosphorylates and activates N-myc downstream-regulated gene 2 (NDRG2), resulting in increased tau phosphorylation via a reduction in Pin1 expression ([@B131]; [@B161]). In summary, the existence of Pin1 in the normal brain may have certain protective functions against AD, as decreased expression or declined activity of Pin1 make neurons vulnerable to pathologies related to AD.

Pin1 and Tau-Related Pathology {#S3}
==============================

The intracellular aggregation of NFTs containing PHFs made of hyperphosphorylated tau is one of the neuropathological hallmarks of AD ([@B44]; [@B12]; [@B48]; [@B129]; [@B10]). Compared with Aβ pathology, which may play a critical role in AD pathogenesis, the prevalence of NFTs has a strong correlation with the severity of cognitive impairment, indicating that tau-related pathology may indicate the status of cognitive deficits and dementia ([@B111]). Encoded by a single gene, MAPT, located on human chromosome 17, tau is a type of microtubule-associated protein and is expressed predominantly in the brain ([@B79]; [@B4]; [@B62]). It is well-established that the physiological function of tau is to maintain microtubule-related functions, such as microtubule assembly and axonal transportation, and the abnormal hyperphosphorylation of tau inhibits normal microtubule functions and alters tau protein stability ([@B31]; [@B14]; [@B6]; [@B123]; [@B137]; [@B142]; [@B124]). Specifically, abnormally phosphorylated tau is detached from microtubules and disrupts microtubule integrity ([@B63], [@B62]). Hyperphosphorylated tau, but not normal tau, is a component of PHF-forming insoluble aggregates and further becomes NFTs ([@B83]; [@B49]; [@B107]). These results indicate that the phosphorylation of tau is essential for the development of tau-related pathology.

The phosphorylation of T231 (pT231), among a number of tau phosphorylation sites, appears to be the first detectable event during AD pretangle formation ([@B103]). pT231 may play a critical role in regulating the conformation and misfolding process of tau ([@B82]; [@B62]). Notably, Pin1 colocalizes with phosphorylated tau, directly binds to pT231-tau, and can restore its biological activity by promoting tau dephosphorylation to bind microtubules and increase microtubule assembly ([@B100], [@B97]; [@B125]; [@B93]). Pin1 facilitates tau dephosphorylation through the proline-directed phosphatase PP2A, which has conformational specificity and dephosphorylates only the *trans* pS/T-P motif ([@B163]). Pin1 has been found to bind PHFs and be trapped in tangles in the AD brain, resulting in the depletion of soluble Pin1 ([@B100]). A recent *in vitro* study showed that reduced Pin1 expression led to the increase of pT231-tau levels ([@B117]). Pin1 has been shown to accelerate the *cis* to *trans* isomerization of pT231-tau, restore its function, and maintain tau levels via proteasome-dependent proteolytic pathway ([@B124]; [@B86]). However, Pin1 has no effect on T231A mutant tau ([@B86]; [@B110]). Interestingly, when hippocampal cultured neurons are exposed to Aβ42 oligomers, Pin1 can be activated to dephosphorylate pT231-tau mediated by PP2A ([@B15]). Notably, studies have showed that microtubule assembly can be significantly increased by unphosphorylated wild-type tau, but not phosphorylated tau which can be restored by PP2A, while the phosphorylated T231A tau is still able to promote microtubule assembly and this ability is not affected by Pin1, suggesting that T231 phosphorylation is critical for Pin1 to maintain microtubule function of tau ([@B110]). Therefore, tau hyperphosphorylation might induce tau aggregation which further sequestrates Pin1, thereby preventing pT231-tau dephosphorylation mediated by PP2A ([Figure 1](#F1){ref-type="fig"}). However, other studies have questioned the specificity of Pin1 targeting site, as they revealed that Pin1 recognized other pS/T-P sites such as pT212 and pS235 motifs in full-length tau, which were the preferred substrates over pT231 motif ([@B139], [@B140]; [@B75]; [@B69]; [@B36]). Besides, other studies also indicated that Pin1 did not regulate the microtubule function of phosphorylated tau ([@B88]; [@B74], [@B76]; [@B72]; [@B96]; [@B130]). Therefore, the specificity of Pin1 targeting sites of tau and the regulatory function of Pin1 toward phosphorylated tau raise other possibilities which need further investigation.

![Pin1-regulated isomerization of pT231-tau against tau-related pathology. There are two strikingly distinct *cis* and *trans* conformations of the pT231 motif of tau after phosphorylation. *Cis*, but not *trans*, pT231-tau promotes tau hyperphosphorylation, the disruption of microtubule assembly, tau aggregation, tangle formation, neuronal apoptosis, and neurodegeneration. Pin1 binds to the pT231-P motif and isomerizes the *cis* form of pT231 to the *trans* form. Low levels of Pin1 due to genetic alteration or the inhibition of Pin1 expression or activity by phosphorylation, oxidation, and sequestration increase the levels of *cis* pT231-tau and may contribute to AD.](fcell-08-00355-g001){#F1}

Recently, the Lu laboratory developed conformation-specific *cis* and *trans* polyclonal and monoclonal pT231-tau antibodies ([@B110]; [@B70]). Specifically, *cis* pT231-tau appears to be more responsible for resistance to tau dephosphorylation and degradation, the disruption of microtubule structure, and vulnerability toward aggregation, and Pin1 catalyzes the isomerization of pT231-tau from *cis* to *trans*, restoring its ability to bind microtubules ([@B100], [@B96]; [@B110]; [@B4], [@B3]). Indeed, *cis* pT231-tau, but not *trans* pT231-tau, is significantly increased and localized to dystrophic neurites in human mild cognitive impairment (MCI) and AD brains ([@B110]). Furthermore, *cis* pT231-tau, but not *trans* pT231-tau, strongly correlates with neurofibrillary degeneration, which is associated with decreased Pin1 levels in the AD hippocampus, in accord with the binding of Pin1 to PHFs leading to the depletion of soluble Pin1 ([@B100]; [@B110]). In addition, *cis* pT231-tau is dramatically induced, facilitates the disruption of axonal microtubules and organelle transport, and finally leads to neuronal apoptosis under neuronal stress ([@B70]). Therefore, the neurotoxic *cis* pT231-tau may function as a critical driver of neurodegeneration, as it can spread among neurons in a prion-like fashion ([@B70]; [@B3]). In tau-overexpressing mice, while *trans* pT231-tau is barely detected in sarkosyl-insoluble fractions, *cis* pT231-tau levels are robustly increased in insoluble fractions in the brain ([@B110]). Interestingly, *cis* pT231-tau has been shown to be a major early driver of traumatic brain injury ([@B70]; [@B5]). These results suggest that the Pin1-regulated isomerization of the *cis* to *trans* conformations of phosphorylated tau is a key mechanism to protect against tau-related pathology. Nevertheless, the *cis* pT231-tau antibody raised against a peptide containing a chemically modified proline instead of a native *cis*-proline has also been questioned, and it is suggested that the specific pT231-P232 bond in phosphorylated tau be majorly in the *trans* conformation ([@B136]; [@B1]; [@B89]).

Thus, Pin1 may maintain normal tau functions through the conformational change of pT231-tau, but its deregulation leads to tau-related pathology during AD development. However, Pin1 acts on different phosphorylation sites of tau and has opposite results of tau function. This discrepancy may be due to the different characteristics of the diverse physiological and pathological conditions. Therefore, more evidence is needed to clarify the role of Pin1 in phosphorylated tau and its function.

Pin1 and App Processing {#S4}
=======================

The extracellular deposition of SPs composed of Aβ peptide derived from APP is another neuropathological hallmark of AD ([@B56]). The human APP gene is located on chromosome 21 and encodes a type I transmembrane protein that plays important roles in neuronal growth, survival, and repair ([@B146]). Upon synthesis in the endoplasmic reticulum, APP undergoes trafficking through the Golgi/trans-Golgi network (TGN) toward the plasma membrane, where it accumulates and internalizes to the endosomes ([@B134]; [@B146]; [@B120]). APP is processed by two different proteolytic processes, the non-amyloidogenic pathway and amyloidogenic pathway ([@B71]; [@B134]; [@B56]; [@B114]; [@B148]). In the non-amyloidogenic processing pathway, APP is cleaved by α-secretase at a site within the sequence of Aβ at the plasma membrane, generating soluble extracellular sAPPα with neurotrophic properties and a C-terminal fragment, C83; C83 is further cleaved by γ-secretase to generate the APP intracellular domain (ACID) and a small p3 fragment, thus avoiding Aβ pathology ([@B38]; [@B138]; [@B134]; [@B56]; [@B146]). In the amyloidogenic processing pathway, APP is internalized to early endosomes through Fe65 and is cleaved by β-secretase to generate soluble sAPPβ and a C-terminal fragment, C99; C99 is further cleaved by γ-secretase in late endosomes to generate the ACID and intact Aβ, inducing Aβ pathology, which is elevated in AD ([@B134]; [@B152]; [@B159]; [@B18]; [@B56]; [@B146]).

APP processing and Aβ generation are regulated by the phosphorylation of the intracellular C-terminal fragment ([@B119]; [@B145]). Notably, the phosphorylation of APP at the T668-P motif is increased in the brains of AD patients compared with those of age-matched controls, facilitating the amyloidogenic processing pathway and Aβ generation ([@B80]). Importantly, Pin1 binds to APP specifically on the phosphorylated T668-P motif *in vitro* and *in vivo* ([@B121]). The binding of Pin1 to phosphorylated T668-P accelerates its isomerization from *cis* to *trans* by over 1,000-fold, as visualized by NMR spectroscopy ([@B126]; [@B127]; [@B121]). The overexpression of Pin1 significantly decreases Aβ secretion *in vitro*, while Pin1 ablation dramatically increases insoluble Aβ42 secretion in cell models and mouse models in an age-dependent manner ([@B121]). Pin1 is colocalized with APP at the plasma membrane and in clathrin-coated vesicles rather than endosomes, and Pin1 inhibition leads to reduced APP levels at the plasma membrane ([@B121], [@B120]). Pin1 influences the levels of Fe65, which can interact with APP and facilitate amyloidogenic APP processing ([@B120], [@B118]). Thus, Pin1 isomerizes APP to the *trans* conformation, controls the intracellular localization and internalization of APP, modulates AICD in a Fe65-dependent manner, and thus exerts a protective function against Aβ pathology, indicating that the Pin1-regulated prolyl isomerization of APP plays a key role in regulating Aβ pathology.

A number of protein kinases responsible for phosphorylating APP at the T668-P motif are abnormally elevated in the AD brain, such as GSK3β, SAPK1b/JNK3, Cdc2, and Cdk5 ([@B163]; [@B80], [@B82]; [@B99]; [@B104]). Among them, GSK3β is a widely expressed proline-directed serine/threonine kinase that is implicated in a number of physiological processes in the nervous system ([@B65]; [@B160]; [@B20]). The aberrant regulation of GSK3β contributes to major neurological disorders, including both familial and sporadic AD ([@B58]; [@B122]). The hyperactivity of GSK3β increases Aβ production, while the inhibition of GSK3β reduces plaques *in vitro* and *in vivo* ([@B91]; [@B41]; [@B37]; [@B61]). Ma and colleagues showed that Pin1 directly binds to the phosphorylated T330-P motif in GSK3β and inhibits its kinase activity *in vitro* and *in vivo* ([@B104]). The suppression of Pin1 causes GSK3β activation, leading to increased levels of T668-phosphorylated APP and amyloidogenic APP processing. In addition, Pin1 promotes APP protein degradation by binding to the phosphorylated T330-P motif of GSK3β ([@B104]; [@B155]). Thus, Pin1 promotes APP protein turnover by inhibiting GSK3β activity, suggesting a novel neuroprotective role of Pin1 against Aβ pathology. However, contrasting results showed that in the Pin1-deficient mice Aβ was lower and Pin1 promoted Aβ production *in vitro* ([@B2]). The discrepancy might due to the usage of β-cleaved carboxy-terminal frangment C99 instead of full-length APP and detection of the mouse brain at an unspecified age. Thus, in healthy neurons, sufficient levels of Pin1 promote the non-amyloidogenic processing pathway of APP and its turnover, reducing Aβ secretion. However, when Pin1 expression is reduced or its activity is inhibited, amyloidogenic APP processing is increased, resulting in Aβ production and Aβ plaques in the AD brain ([Figure 2](#F2){ref-type="fig"}).

![Pin1-mediated APP processing. Pin1 binds to the pT668-P motif of APP, accelerates its isomerization from *cis* to *trans*, stabilizes APP at the plasma membrane, and ultimately promotes the non-amyloidogenic processing pathway. Moreover, conformational changes in APP may affect the binding of Fe65, thus preventing the amyloidogenic processing pathway. Furthermore, Pin1 promotes APP protein turnover by decreasing GSK3β activity. Under physiological conditions, sufficient levels of Pin1 protect healthy neurons against Aβ pathology. When Pin1 expression/activity is inhibited, the amyloidogenic processing pathway is dominant, resulting in Aβ production and plaques.](fcell-08-00355-g002){#F2}

Pin1 Mouse Models of AD {#S5}
=======================

Animal models recapitulating the characteristics of AD are of vital importance not only for performing *in vivo* studies that explore molecular mechanisms but also for providing preclinical subjects for potential drug candidates. Due to research on familial forms of AD, transgenic mouse models have been developed and widely used ([@B43]; [@B35]; [@B59]; [@B85]; [@B50]). However, mutated tau and APP overexpression mice do not recapitulate all features of AD ([@B32]). Pin1 knockout (KO) mice were initially created to explore the function of Pin1 in mammalian cells, and they were viable and developed normally to adulthood ([@B42]). Importantly, Pin1 KO mice are the first mouse models to show both tau-related and Aβ pathology when a specific gene is deleted ([@B87]; [@B121]; [@B99]; [@B82]). Pin1 KO mice show tau hyperphosphorylation leading to age-dependent tau filament formation and NFT-like pathologies compared with their wild-type littermates ([@B87]). Pin1-KO mice also show neuronal loss and progressive age-dependent motor and behavioral deficits, such as abnormal limb-clasping reflexes, hunched posture, reduced mobility, and eye irritation ([@B87]). When neuron-specific Pin1 transgenic (Tg) mice are bred with wild-type tau Tg mice, Pin1 overexpression reduces tau hyperphosphorylation, NFT specific conformations, and aggregation ([@B86]). Surprisingly, in Tg mice overexpressing human P301L mutant tau, which causes frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Pin1 KO drastically decreases the total tau levels and the hyperphosphorylation of tau, while Pin1-Tg promotes tau hyperphosphorylation, tau aggregation, and NFT conformation ([@B86]). This unexpected discrepancy was explained that the mutation might somehow render the pT231 motif in tau to be favored in the *trans* conformations ([@B86]). Therefore, Pin1 overexpression might accelerate the isomerization of the protective *trans* conformation to the pathogenic *cis* conformation, whereas Pin1 inhibition contributes to maintaining the *trans* conformation, facilitating P301L tau degradation ([@B86]). Since no tau mutations have been found in AD, tau-related pathology induced by exogenous overexpression of mutant tau may be different from human AD in terms of molecular regulatory mechanisms. In addition, when Pin1 KO mice have been bred with tau-Tg mice, these mice exhibit increased *cis* pT231-tau, but decreased *trans* pT231-tau levels, supporting the Pin1-mediated suppression of tau-related neurodegeneration in mice ([@B110]).

Pin1 ablation in mice also affects APP processing in APP-overexpressing mouse brains ([@B121]). Compared with the wild-type littermates, Pin1 KO mice exhibit increased levels of insoluble Aβ42, the major toxic species, at 15 months of age, but not at 6 months of age, suggesting that Pin1 KO promotes amyloidogenic APP processing in an age-dependent manner ([@B121]). Pin1 ablation in APP-Tg2576 mice significantly induces insoluble Aβ42 species and increases soluble APPβ levels at 6 months of age. These Aβ42 species are mainly localized to multivesicular bodies of neurons that experience Aβ plaque pathology ([@B121]). Thus, Pin1 is a unique protein, the deletion of which causes age-dependent tau-related and Aβ pathologies, suggesting evidence of a molecular link between tangles and plagues and a protective role of Pin1 against AD.

Pin1 in Diagnostic and Therapeutic Strategies for AD {#S6}
====================================================

Following a series of abnormal tau hyperphosphorylation that induces the formation of NFTs, pT231 appears to be the first detectable phosphorylation site of tau ([@B103]). Due to the elevated sequestration of pT231-tau into the tangles and the decreased levels of pT231-tau that enter the cerebrospinal fluid (CSF), pT231-tau provides an early and specific biomarker of AD progression ([@B53]; [@B141]). The assessment of pT231-tau in the CSF has been regarded as a good predictor of conversion from MCI to AD ([@B39]). However, the presence of individual variations using pT231-tau might impede its application as a standardized test, whereas whether the existence of distinct forms (*cis* or *trans*) of pT231-tau helps to explain the variations remains to be investigated ([@B110]). Notably, *cis* and *trans* pT231-tau forms, which are regulated by Pin1, can be distinguished by recently developed conformation-specific antibodies ([@B110]; [@B70]). Importantly, *cis* pT231-tau appears early in MCI, is pathologically more relevant, and contributes to AD ([@B110]). Current diagnostic approaches using CSF or positron emission tomography (PET) are either invasive or expensive, making it difficult to achieve early diagnosis using these approaches ([@B149]; [@B90]). Commonly known markers used as diagnostic methods are often detectable months or years after the initiation of AD pathogenesis. Therefore, early detectable concentrations of *cis* pT231-tau, changes in *cis* pT231-tau levels, and the ratio of *cis* pT231-tau to *trans* pT231-tau in body fluids and blood from normal and AD patients might be better and more standardized biomarkers for early diagnosis.

To date, AD remains incurable, and a pool of issues remains to be solved. First and foremost, whether Aβ pathology occurs first and induces tau-related pathology, or vice versa, is still controversial. The answer to this question may influence the efficacy of targeted therapies specific for Aβ or tau. Moreover, available therapeutic strategies primarily focus on slowing down the progression of cognitive decline and neurodegeneration rather than targeting essential pathways ([@B118]). Furthermore, the administration of drugs at late stages due to the lack of early diagnosis may dramatically attenuate the efficacy since AD usually takes more than a decade to develop. Notably, the discovery of the Pin1-catalyzed *cis/trans* isomerization of phosphorylated S/T-P motifs in tau and APP and *cis* pT231-tau, but not *trans* pT231-tau, as an early and potent driver in MCI and AD, offers an attractive and promising therapeutic strategy for AD. A generation of mouse monoclonal antibodies specific for *cis* pT231-tau has been developed and shown to eliminate pathologic *cis* pT231-tau and prevent tau-related pathology development and spread ([@B70]; [@B5]). Importantly, immunotherapy employing this strategy specifically aims at the earliest possible pathogenic form of tau rather than the physiological *trans* form of pT231-tau with normal functions in AD ([@B70]). Thus, further humanization of the *cis* pT231-tau antibody is conducive to developing novel therapeutic strategies for AD.

Because Pin1 plays an important role in preventing tau-related and Aβ pathologies in AD, the upregulation and/or activation of Pin1 could be a viable strategy for AD treatment. However, Pin1 overexpression contributes to a number of cancers, eliminating the possibility of direct administration ([@B164]). Aberrant Pin1 elevation has been shown to be involved in many signaling events such as cell cycle coordination, chromosome instability, proliferation, migration, metastasis, and apoptosis in cancer ([@B164]). Indeed, Pin1 is known to activate 56 oncogenes and inactivate 26 tumor suppressors by regulating their activity, protein interaction, stability, and cellular localization ([@B24]; [@B162]). Pin1 overexpression in mammary gland induces chromosome instability and leads to breast cancer development and Pin1 ablation effectively prevents tumorigenesis by overexpressing Neu in animal models ([@B154]; [@B143]). Therefore, direct Pin1 activation in brain might cause malignant brain tumor. If we could specifically deliver Pin1 activator to neurons, it might be useful because neurons do not divide or proliferate. In addition, therapeutic strategies targeting Pin1 also focus on the upstream regulators of Pin1 such as DAPK1 or targets such as *cis* or *trans* pT231-tau. Indeed, the inhibition of DAPK1 has been shown to attenuate tau hyperphosphorylation and Aβ production ([@B66], [@B67], [@B68]; [@B161]; [@B23]). Thus, Pin1-related therapeutic strategies might be valuable in the treatment of AD.

Conclusion {#S7}
==========

The peptidyl-prolyl *cis/trans* isomerase Pin1 is a crucial regulator that is implicated in a wide variety of physiological and pathological activities. The deregulation of Pin1 expression and/or activity is associated with the development of cancer and neurodegeneration, including AD. Interestingly, Pin1 regulates the conformational change of both tau and APP and has protective effects against tau-related and Aβ pathology, suggesting that Pin1 might be a novel and promising candidate for exploring the molecular mechanisms, diagnosis, and treatment of AD.

The availability of drug candidates largely depends on animal models. Currently, many types of single or biogenic Tg mice are broadly used to study tau-related and Aβ pathologies; however, these mice fail to recapitulate all aspects of human AD. Pin1 KO mice develop both tau-related and Aβ pathologies in an age-dependent manner by employing endogenous tau and APP proteins, providing an attractive *in vivo* model for AD research and drug testing. Novel therapeutic strategies such as *cis* pT231-tau antibodies that target conformation-specific phosphorylated tau or small molecules such as DAPK1 inhibitors might provide effective treatment for human AD. However, many questions, including how to regulate Pin1 levels due to its dual roles in cancer and AD, how to overcome the blood-brain barrier for antibody treatment, and how to validate a suitable time for drug administration in the early stage of AD, remain to be answered before clinical validation. Moreover, Pin1 has been shown to lead different direction of tau phosphorylation and APP processing depending on cellular context. More research is urgently needed to illuminate the underlying roles of Pin in the molecular regulation, early diagnosis, potential treatment, and possible prevention of AD.
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